MyMedR

Displaying all 6 publications

Abstract:

Sort:

Identity of the tree-spider crab, Parasesarma leptosoma (Hilgendorf, 1869 (Decapoda: Brachyura: Sesarmidae), with descriptions of seven new species from the Western Pacific

Li JJ, Rahayu DL, Ng PKL

Zootaxa, 2018 Sep 19;4482(3):451-490.
PMID: 30313809 DOI: 10.11646/zootaxa.4482.3.2

The identity of the tree-spider crab, Parasesarma leptosoma (Hilgendorf, 1869) (family Sesarmidae), which is believed to be widely distributed in the Indo-West Pacific, is reassessed and shown to be a species-complex with nine species, seven of which are here described as new. Parasesarma leptosoma sensu stricto is now restricted to South and East Africa; and P. limbense (Rathbun, 1914) from Sulawesi, which had been regarded as a junior synonym, is here recognized as a valid species. The following species are described as new: P. gecko n. sp. from Vanuatu, Fiji, Guam and Japan; P. macaco n. sp. from Taiwan and the Philippines; P. kui n. sp. from Taiwan; P. parvulum n. sp. from the Philippines; P. gracilipes n. sp. from Indonesian Papua; P. purpureum n. sp. from Malaysia; and P. tarantula n. sp. from Sulawesi, Indonesia. The nine species of the Parasesarma leptosoma species-complex can be separated by the different shapes of their carapaces, the form of the dactylar tubercles on the male chelipeds, proportions of their ambulatory legs and the structure of the male first gonopod.
Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East

Alshamiri M, Ghanaim MMA, Barter P, Chang KC, Li JJ, Matawaran BJ, et al.

Int J Gen Med, 2018;11:313-322.
PMID: 30050317 DOI: 10.2147/IJGM.S160555

Cardiovascular disease (CVD) is a growing burden across the world. In Asia and the Middle East, in particular, CVD is among the most prevalent and debilitating diseases. Dyslipidemia is an important factor in the development of atherosclerosis and associated cardiovascular events, and so effective management strategies are critical to reducing overall cardiovascular risk. Multiple dyslipidemia guidelines have been developed by international bodies such as the European Society of Cardiology/European Atherosclerosis Society and the American College of Cardiology/American Heart Association, which all have similarities in practice recommendations for the optimal management of dyslipidemia. However, they differ in certain aspects including pharmacological treatment, lifestyle modification and the target levels used for low-density lipoprotein cholesterol. The evidence behind these guidelines is generally based on data from Western populations, and their applicability to people in Asia and the Middle East is largely untested. As a result, practitioners within Asia and the Middle East continue to rely on international evidence despite population differences in lipid phenotypes and CVD risk factors. An expert panel was convened to review the international guidelines commonly used in Asia and the Middle East and determine their applicability to clinical practice in the region, with specific recommendations, or considerations, provided where current guideline recommendations differ from local practice. Herein, we describe the heterogeneous approaches and application of current guidelines used to manage dyslipidemia in Asia and the Middle East. We provide consensus management recommendations to cover different patient scenarios, including primary prevention, elderly, chronic kidney disease, type 2 diabetes, documented CVD, acute coronary syndromes and family history of ischemic heart disease. Moreover, we advocate for countries within the Asian and Middle East regions to continue to develop guidelines that are appropriate for the local population.
Fulltext Tackling cardiometabolic risk in the Asia Pacific region

Li JJ, Yeo KK, Tan K, Ako J, Krittayaphong R, Tan RS, et al.

Am J Prev Cardiol, 2020 Dec;4:100096.
PMID: 34327472 DOI: 10.1016/j.ajpc.2020.100096

With the global spread of abdominal obesity, cardiovascular disease continues to spread to all countries of the world. Given the large population, the challenges presented by cardiometabolic risk in the Asia Pacific region are considerable. In addition to the clinical consequences of cardiovascular disease, in terms of its morbidity and mortality, the diversity of the Asia Pacific region brings heterogeneity in approaches to prevention, diagnosis and treatment of cardiometabolic risk. In this manuscript, we will review the current state of knowledge of cardiometabolic risk in Asia Pacific and highlight the needs moving forward to tackle this public health challenge.
Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects

Li JJ, Liu HH, Wu NQ, Yeo KK, Tan K, Ako J, et al.

Expert Opin Drug Metab Toxicol, 2020 Sep;16(9):837-851.
PMID: 32729743 DOI: 10.1080/17425255.2020.1802426

INTRODUCTION: Statins have been established as the standard of care for dyslipidemia and preventing cardiovascular diseases while posing few safety concerns. However, misconceptions about statin intolerance lead to their underuse, indicating a need to improve the understanding of the safety of this treatment.
AREAS COVERED: We searched PubMed and reviewed literatures related to statin intolerance published between February 2015 and February 2020. Important large-scale or landmark studies published before 2015 were also cited as key evidence.
EXPERT OPINION: Optimal lowering of low-density lipoprotein cholesterol with statins substantially reduces the risk of cardiovascular events. Muscle adverse events (AEs) were the most frequently reported AEs by statin users in clinical practice, but they usually occurred at a similar rate with statins and placebo in randomized controlled trials and had a spurious causal relationship with statin treatment. We proposed a rigorous definition for identifying true statin intolerance and present the criteria for defining different forms of muscle AEs and an algorithm for their management. True statin intolerance is uncommon, and every effort should be made to exclude false statin intolerance and ensure optimal use of statins. For the management of statin intolerance, statin-based approaches should be prioritized over non-statin approaches.
Fulltext Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease in the Asia-Pacific Region

Tada H, Yeo KK, Li JJ, Tan K, Ako J, Krittayaphong R, et al.

JACC Asia, 2021 Dec;1(3):294-302.
PMID: 36341217 DOI: 10.1016/j.jacasi.2021.08.008

Approximately one-half of the phenotypic susceptibility to atherosclerotic cardiovascular disease (ASCVD) has a genetic basis. Although individual allelic variants generally impart a small effect on risk for ASCVD, an emerging body of data has shown that the aggregation and weighting of many of these genetic variations into "scores" can further discriminate an individual's risk beyond traditional risk factors alone. Consistent with the theory of population genetics, such polygenic risk scores (PRS) appear to be ethnicity specific because their elements comprise single-nucleotide variants that are always ethnicity specific. The currently available PRS are derived predominantly from European ancestry and thus predictably perform less well among non-European participants, a fact that has implications for their use in the Asia-Pacific region. This paper describes the current state of knowledge of PRS, the available data that support their use in this region, and highlights the needs moving forward to safely and effectively implement them in clinical care in the Asia-Pacific region.
Fulltext An international multidisciplinary consensus statement on MAFLD and the risk of CVD

Zhou XD, Targher G, Byrne CD, Somers V, Kim SU, Chahal CAA, et al.

Hepatol Int, 2023 Aug;17(4):773-791.
PMID: 37204656 DOI: 10.1007/s12072-023-10543-8

BACKGROUND: Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25-30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfunction)-associated fatty liver disease (MAFLD) has been proposed for this condition. MAFLD is closely intertwined with obesity, type 2 diabetes mellitus and atherogenic dyslipidemia, which are established cardiovascular risk factors. Unlike CVD, which has received attention in the literature on fatty liver disease, the CVD risk associated with MAFLD is often underestimated, especially among Cardiologists.
METHODS AND RESULTS: A multidisciplinary panel of fifty-two international experts comprising Hepatologists, Endocrinologists, Diabetologists, Cardiologists and Family Physicians from six continents (Asia, Europe, North America, South America, Africa and Oceania) participated in a formal Delphi survey and developed consensus statements on the association between MAFLD and the risk of CVD. Statements were developed on different aspects of CVD risk, ranging from epidemiology to mechanisms, screening, and management.
CONCULSIONS: The expert panel identified important clinical associations between MAFLD and the risk of CVD that could serve to increase awareness of the adverse metabolic and cardiovascular outcomes of MAFLD. Finally, the expert panel also suggests potential areas for future research.